Hubei Huaqiang High-Tech Co. Ltd. A (688151) fair value: what the stock is really worth
We calculate from audited financials what Hubei Huaqiang High-Tech Co. Ltd. A is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Hubei Huaqiang High-Tech Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
57‑month range ¥11.23 – ¥42.49 · fair‑value band ¥7.47 – ¥7.53 · the ¥17.82 price screens above the ¥7.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Hubei Huaqiang High-Tech Co., Ltd. research, develops, produces, and sells special protective equipment, pharmaceutical packaging, and medical devices in China. The company operates as a chemical defense military enterprise in special protection.
Show more
Hubei Huaqiang High-Tech Co., Ltd. research, develops, produces, and sells special protective equipment, pharmaceutical packaging, and medical devices in China. The company operates as a chemical defense military enterprise in special protection. It offers personal protective equipment, such as anti-virus clothing and boot covers, and gas masks; collective protective equipment, comprising cooperative supporting and demobilized troops products, pre-filters, air inlet components, particle filters, filter absorbers, poison filter ventilation devices, and collective protection system equipment; and chemical defense equipment for national civil air defense projects, such as civil air defense filters and doors, and impregnated carbon. It also provides pharmaceutical packaging and medical devices, such as medicinal butyl rubber stoppers, multi-layer co-extruded films, aluminum-plastic covers, medical masks, and medical protective clothing; conventional and film-coated rubber stoppers, and rubber components for prefilled syringes; and medical disposable protective clothing, disposable medical masks, medical surgical and protective masks, and other medical protective products. In addition, the company engages in business and manufacturing activities. Hubei Huaqiang High-Tech Co., Ltd. was founded in 2001 and is headquartered in Yichang, China.
Stock analysis
Hubei Huaqiang High-Tech Co. Ltd. A (688151) currently trades at ¥17.82, while our model-based Fair Value estimate is ¥7.53, implying the stock looks roughly 136.6% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥8.49 per share, and 0 of the 23 models we run sit above the ¥17.82 price.
Bear case: the Earnings-Based group reads lowest at ¥1.03, and 23 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥7.47 (bear) to ¥7.53 (bull), the price of ¥17.82 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Hubei Huaqiang High-Tech Co. Ltd. A reported revenue of 628M CNY in FY2025 versus 1.3B CNY in FY2021, a compound −16.2%/yr. Reported net income was 42.8M CNY in FY2025, compounding −39.5%/yr from FY2021.
Key figures
Market cap 6.1B CNY (≈ $915M) · P/E ratio 137.1 · P/S ratio 9.33 · EPS (TTM) ¥0.1300 · Dividend yield 0.3% · Net margin 6.8% · Return on equity 1.1% · Return on assets (EBIT) 1.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −58%, 688151 screens richer than that median.
Fair Value models
Bear ¥7.47Fair Value ¥7.53Bull ¥7.53
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (¥0.0521 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.32/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.5%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.8%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ −44.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−45.0%
Dividend (yield on the price)0.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 2%
⚠ Rate on operating basis: 2025 sits 90% above its own trend.
Compare Hubei Huaqiang High-Tech Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 202 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score56 · Below median
Fair Value upside−84% · Bottom 25%
Profitability
Return on equity (TTM)1% · Below median
Return on assets0% · Bottom 25%
Net margin (TTM)7% · Above median
Operating margin (TTM)−4% · Bottom 25%
Growth and dividend
Revenue growth60% · Top 25%
Dividend yield (TTM)0.3% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)137.1× · Priciest 25%
P/B1.42× · Cheaper than median
P/S (TTM)9.01× · Priciest 25%
P/FCF159.1× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)100· sector 24
PAST (return on equity)4· sector 25
HEALTH (low debt)0· sector 96
DIVIDEND (yield)6· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hubei Huaqiang High-Tech Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688151
Frequently asked questions
Is Hubei Huaqiang High-Tech Co. Ltd. A (688151) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ¥7.53 versus a price of ¥17.82, about −58% upside (overvalued).
What is the fair value of 688151?
Our model-based fair value for Hubei Huaqiang High-Tech Co. Ltd. A is ¥7.53 (as of Sep 13, 2026), built from audited fundamentals. The current price: ¥17.82.
What is the quality score of 688151?
Hubei Huaqiang High-Tech Co. Ltd. A has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
Our model-based price target is the fair value of ¥7.53 (as of Sep 13, 2026) from 23 valuation models. Cautious scenario ¥7.47, optimistic scenario ¥7.53. It is a calculation from audited fundamentals, not an analyst target.
What is the Hubei Huaqiang High-Tech Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥7.53, about −58% upside versus a price of ¥17.82 (overvalued). Cautious scenario ¥7.47, optimistic scenario ¥7.53. The calculation is refreshed regularly with new filings.
What is the revenue of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
Hubei Huaqiang High-Tech Co. Ltd. A reported trailing-twelve-month revenue of about 667M CNY (latest available figure, as of Sep 13, 2026).
Does Hubei Huaqiang High-Tech Co. Ltd. A pay a dividend?
Hubei Huaqiang High-Tech Co. Ltd. A currently shows a dividend yield of about 0.31% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hubei Huaqiang High-Tech Co. Ltd. A it is ¥7.53 per share (as of Sep 13, 2026), against a price of ¥17.82. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Hubei Huaqiang High-Tech Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 688151 trades above its calculated fair value: price ¥17.82, fair value ¥7.53, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688151?
No. The price is what the market pays today (¥17.82); the fair value is what the company's own numbers justify (¥7.53). For Hubei Huaqiang High-Tech Co. Ltd. A the two are ¥10.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hubei Huaqiang High-Tech Co. Ltd. A worth?
The market values Hubei Huaqiang High-Tech Co. Ltd. A at about 6.1B CNY (market capitalisation, as of Sep 13, 2026). Per share that is ¥17.82; our models calculate a fair value of ¥7.53 per share.
What do the bullish and bearish scenarios say about 688151?
Our models span a range for Hubei Huaqiang High-Tech Co. Ltd. A: cautious scenario ¥7.47, base ¥7.53, optimistic ¥7.53 per share (as of Sep 13, 2026, price ¥17.82). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688151?
Hubei Huaqiang High-Tech Co. Ltd. A trades at a price-to-earnings ratio of 137.1 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥7.53 is built from several models across several years. Other multiples: P/B 1.4, P/S 9.0.
How solid is the balance sheet of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
Balance-sheet figures for Hubei Huaqiang High-Tech Co. Ltd. A (as of Sep 13, 2026): return on equity 1.1%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 688151 from its 52-week high?
Hubei Huaqiang High-Tech Co. Ltd. A trades at ¥17.82, about 40% below its 52-week high of ¥29.92 and 13% above the low of ¥15.73 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.53 is for.
Which stocks are comparable to Hubei Huaqiang High-Tech Co. Ltd. A?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hubei Huaqiang High-Tech Co. Ltd. A stock attractive at the current price?
The data as of Sep 13, 2026: price ¥17.82, calculated fair value ¥7.53 (−58%), Quality Score 56/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688151 calculated?
We run Hubei Huaqiang High-Tech Co. Ltd. A through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥7.53, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Hubei Huaqiang High-Tech Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Hubei Huaqiang High-Tech Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥7.53). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥7.47 to ¥7.53), unusually little disagreement for a valuation.
Key figures of Hubei Huaqiang High-Tech Co. Ltd. A
How large is the market capitalisation of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
The market capitalisation of Hubei Huaqiang High-Tech Co. Ltd. A is 6.1B CNY (≈ $915M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
The price-to-sales ratio of Hubei Huaqiang High-Tech Co. Ltd. A is 9.33 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
Earnings per share at Hubei Huaqiang High-Tech Co. Ltd. A are ¥0.1300 (price ÷ EPS = P/E 137.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
The dividend yield of Hubei Huaqiang High-Tech Co. Ltd. A is 0.3% (payout 43.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
The net margin of Hubei Huaqiang High-Tech Co. Ltd. A is 6.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
The return on equity (ROE) of Hubei Huaqiang High-Tech Co. Ltd. A is 1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
On an EBIT basis the return on assets of Hubei Huaqiang High-Tech Co. Ltd. A is 1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
The operating margin of Hubei Huaqiang High-Tech Co. Ltd. A is −4.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
Revenue at Hubei Huaqiang High-Tech Co. Ltd. A is growing +59.5% versus a year earlier (3y avg +2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hubei Huaqiang High-Tech Co. Ltd. A (688151)?
Earnings per share at Hubei Huaqiang High-Tech Co. Ltd. A are growing +280% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hubei Huaqiang High-Tech Co. Ltd. A (688151) generate?
The free cash flow of Hubei Huaqiang High-Tech Co. Ltd. A is 5.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Hubei Huaqiang High-Tech Co. Ltd. A in the live analysis
One click puts Hubei Huaqiang High-Tech Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
